UP FRONT
March 9 – 12, 2016
March 31 – April 2, 2016
April 16 – 20, 2016
American Academy of Hospice and Palliative Medicine Annual Assembly
National Comprehensive Cancer Network
Annual Conference
American Association of Cancer Research
Annual Meeting
Chicago, Illinois
This educational event brings together physicians,
nurses, and other health-care providers to share
research, clinical best practices, and practice-related
guidance to improve quality of life for patients and
families facing serious or life-threatening conditions.
Hollywood, Florida
The theme of this year’s NCCN Annual Conference
is “Advancing the Standard of Cancer Care,” and
attendees will discuss the latest cancer therapies,
quality initiatives, and selected NCCN Clinical Practice
Guidelines in Oncology.
New Orleans, Louisiana
The AACR Annual Meeting will highlight the latest
discoveries in every area of cancer research, from
molecular biology to clinical studies, epidemiology,
prevention, and survivorship.
Mule-drawn carriages in New Orleans.
reactions was 3/3 (100%) compared to 3/8 (38%) in patients with normal renal function. Additionally, the
AUC of MMAE (component of ADCETRIS) was approximately 2-fold higher in patients with severe renal
impairment compared to patients with normal renal function. Due to higher MMAE exposure, ≥Grade 3
adverse reactions may be more frequent in patients with severe renal impairment compared to patients with
normal renal function.
Hepatic Impairment
Avoid the use of ADCETRIS in patients with moderate or severe hepatic impairment.
The liver is a route of clearance for MMAE. The pharmacokinetics and safety of brentuximab vedotin and
MMAE were evaluated after the administration of 1.2 mg/kg of ADCETRIS to patients with mild (Child-Pugh A;
n=1), moderate (Child-Pugh B; n=5) and severe (Child-Pugh C; n=1) hepatic impairment. In patients with
moderate or severe hepatic impairment, the rate of ≥Grade 3 adverse reactions was 6/6 (100%) compared
to 3/8 (38%) in patients with normal hepatic function. Additionally, the AUC of MMAE was approximately
2.2-fold higher in patients with hepatic impairment compared to patients with normal hepatic function.
OVERDOSAGE
There is no known antidote for overdosage of ADCETRIS. In case of overdosage, the patient should be
closely monitored for adverse reactions, particularly neutr